Extended Data Fig. 6: A single dose of mRNA-1273 elicits robust antibody responses.
From: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
a–c, BALB/cJ mice (n = 10/group) were immunized with 0.01 (green), 0.1 (blue), 1 μg (red), or 10 μg (purple) of mRNA-1273. Sera were collected 2 (unfilled circles) and 4 (filled circles) weeks post-immunization and assessed for SARS-CoV-2 S-specific total IgG by ELISA (a) and neutralizing antibodies against homotypic SARS-CoV-2 pseudovirus (b). c, S-specific IgG2a and IgG1 were also measured by ELISA, and IgG2a to IgG1 subclass ratios were calculated. In a, b, Time points were compared within each dose level by two-sided Wilcoxon signed-rank test, and doses were compared 4 weeks post-boost by Kruskal–Wallis ANOVA with Dunn’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. c, Doses were compared by two-sided Mann–Whitney U-test, and no significance was found. Data are presented as GMT ± geometric s.d. (a, b) or mean ± s.d. (c), and dotted lines represent assay limits of detection.
